1. Home
  2. ANIX vs PROV Comparison

ANIX vs PROV Comparison

Compare ANIX & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.81

Market Cap

100.6M

Sector

Health Care

ML Signal

HOLD

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

HOLD

Current Price

$17.05

Market Cap

103.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
PROV
Founded
1982
1956
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Savings Institutions
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
100.6M
103.7M
IPO Year
2013
2009

Fundamental Metrics

Financial Performance
Metric
ANIX
PROV
Price
$2.81
$17.05
Analyst Decision
Strong Buy
Hold
Analyst Count
3
2
Target Price
$8.67
$16.25
AVG Volume (30 Days)
111.0K
6.2K
Earning Date
05-27-2026
04-28-2026
Dividend Yield
N/A
3.26%
EPS Growth
12.82
N/A
EPS
N/A
0.68
Revenue
$210,000.00
N/A
Revenue This Year
N/A
$4.14
Revenue Next Year
N/A
$3.70
P/E Ratio
N/A
$25.07
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$14.85
52 Week High
$5.46
$17.42

Technical Indicators

Market Signals
Indicator
ANIX
PROV
Relative Strength Index (RSI) 43.41 56.17
Support Level $2.81 $16.93
Resistance Level $3.12 $17.38
Average True Range (ATR) 0.16 0.21
MACD -0.03 -0.04
Stochastic Oscillator 15.28 31.48

Price Performance

Historical Comparison
ANIX
PROV

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

Share on Social Networks: